Drug Profile
Teneligliptin - Mitsubishi Tanabe Pharma Corporation
Alternative Names: MP-513; Tenelia; teneligliptin hydrobromide hydrateLatest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Handok Inc; Mitsubishi Tanabe Pharma Corporation
- Class Antihyperglycaemics; Ketones; Piperazines; Pyrazoles; Small molecules; Thiazolidines
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 04 Mar 2024 Mitsubishi Tanabe Pharma Corporation plans to terminate its marketing agreement for Canagliflozin in Japan in 2 September 2024
- 17 Aug 2022 Handok initiates enrolment in a phase III trial for Type 2 diabetes mellitus in South Korea (NCT05504239)
- 10 Feb 2022 Mitsubishi Tanabe Pharma Corporation plans to launch for teneligliptin for Type 2 diabetes mellitus in China in 2022